What Is the Difference Between Cellular and Fibrotic NSIP?

First, it is important to know that the word “pneumonia” in non-specific interstitial pneumonia (NSIP) does not mean you have a bacterial or viral infection. Instead, it describes a specific pattern of inflammation and scarring in the lung tissue.

When you are diagnosed with NSIP, your multidisciplinary care team (which often includes pulmonologists, radiologists, and rheumatologists) will review your medical history, breathing tests, and high-resolution CT scans. Based on this information—and sometimes a lung biopsy—they may describe your condition as “cellular,” “fibrotic,” or a mix of both.

Cellular NSIP means the lungs are actively inflamed. Fibrotic NSIP means there is established scarring in the lungs ^[1]. Understanding these differences can help you make sense of your treatment options and long-term outlook.

Cellular NSIP: The Inflammatory Pattern

In cellular NSIP, the lung tissue contains a high number of inflammatory cells, mostly lymphocytes ^[1].

• Treatment expectations: Because inflammation is an active process, cellular NSIP often responds well to specialist-selected treatments designed to calm the immune system, such as corticosteroids (like prednisone) or other immunosuppressive drugs ^[1].
• Outlook: Because the condition is driven by inflammation rather than permanent scarring, the long-term prognosis for cellular NSIP is often favorable ^[2]. Patients with cellular disease generally have better baseline (starting point) lung function than those with fibrotic disease ^[3]. However, the disease can sometimes relapse (flare up again) if medications are reduced too quickly, so careful monitoring remains essential.

Fibrotic NSIP: The Scarring Pattern

In fibrotic NSIP, the lung tissue has built up excess collagen (the tough protein that forms scar tissue), leading to established fibrosis ^[1][4]. This pattern can be seen on CT scans as reticulation (a net-like pattern of lines) or traction bronchiectasis (widened airways pulled apart by the surrounding scar tissue) ^[1].

• Treatment expectations: Scar tissue cannot be reversed by anti-inflammatory drugs. Treatment for fibrotic NSIP is highly individualized. If active inflammation exists alongside the scarring, or if an autoimmune disease is driving the condition, doctors may use carefully selected immunosuppressive medications (such as azathioprine or mycophenolate) ^[4][1]. However, these are not automatic defaults for everyone. If the fibrosis shows objective signs of worsening over time, specialists may consider anti-fibrotic drugs (such as nintedanib). Anti-fibrotics do not remove existing scar tissue, but they are used to help slow the loss of lung function ^[5][6].
• Outlook: While the word “fibrotic” can be frightening, it does not automatically mean a rapid, relentless decline. Many patients achieve clinical stability (where symptoms and test results do not significantly worsen) for years. For context, in one specific study of patients with biopsy-confirmed fibrotic NSIP, about 94% of patients survived for at least five years after diagnosis ^[4]. Keep in mind, however, that survival does not guarantee symptom-free breathing, and fibrotic NSIP generally carries a higher risk of persistent impairment or progression than cellular NSIP ^[4][7].

The Reality: Mixed Patterns and Diagnosis

Many patients do not fall perfectly into one category. When doctors look at lung tissue under a microscope, they often find a mixed pattern of both cellular inflammation and fibrotic scarring ^[8].

It is also important to understand that your subtype cannot always be definitively assigned from a CT scan alone. A CT scan can strongly suggest a cellular or fibrotic pattern, but measuring the exact amount of inflammation versus scarring requires a surgical lung biopsy ^[8]. Because a biopsy carries meaningful risks, it is not necessary or safe for every patient. Your doctors will tailor your treatment based on your entire clinical picture, not just a single label.

Why Your Subtype Isn’t the Whole Story

Your doctors will not base your prognosis purely on whether you have cellular or fibrotic NSIP ^[9]. Several other factors provide a clearer picture of your health:

• The underlying cause: NSIP can be idiopathic (meaning no cause is ever found). However, it is frequently linked to connective tissue diseases (like systemic sclerosis/scleroderma or rheumatoid arthritis), environmental exposures (such as mold or birds), or certain medications ^[10]. Identifying an underlying cause can substantially change your treatment plan ^[7][2]. Be sure to tell your doctor about any joint pain, skin rashes, dry eyes, acid reflux, Raynaud’s (fingers turning white/blue in the cold), or occupational exposures.
• Your lung function over time: How your lungs perform on pulmonary function tests—especially your FVC (forced vital capacity, or how much air you can forcefully exhale) and DLCO (diffusing capacity, which measures oxygen transfer)—is a critical indicator of your outlook ^[4][7]. Doctors look for stability over intervals like 3 to 12 months. While a stable period is reassuring, normal variations happen, and continued follow-up is necessary ^[7][11].
• Defining “progression”: Doctors do not diagnose progression based on one bad test. It is judged by a combination of worsening symptoms, downward trends in FVC and DLCO, increased oxygen needs, and new scarring on CT scans ^[7].
• The extent of the disease: The total amount of scarring visible on your CT scan and your baseline breathing capacity play a major role in your overall health and treatment decisions ^[12][13].

Safety, Monitoring, and Next Steps

Because NSIP treatments can involve powerful medications, safety and supportive care are crucial parts of your journey:

• Medication risks: Immunosuppressants and anti-fibrotics carry risks, including an increased chance of infection, liver changes, or low blood counts. You will need regular blood tests to monitor your body’s response. Do not start, stop, or change these medications without speaking to your specialist.
• When to seek help: Do not wait for your next routine appointment if you experience worsening breathlessness, new or increasing oxygen needs, chest pain, fever, or confusion. Report rapidly changing symptoms to your care team immediately.
• Supportive care: Medical treatment for NSIP goes beyond pills. Ask your doctor about pulmonary rehabilitation (exercise and education programs tailored for lung conditions), whether you need an oxygen assessment for physical activity, and keeping up to date with vaccinations (like flu and pneumonia vaccines) to protect your lungs.